This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Dec 20;190(1):3-4.

doi: 10.1093/bjd/ljad319.

Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis

Antonia Lloyd-Lavery¹

Affiliations

PMID: 37658936
DOI: 10.1093/bjd/ljad319

Editorial

Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis

Antonia Lloyd-Lavery. Br J Dermatol. 2023.

. 2023 Dec 20;190(1):3-4.

doi: 10.1093/bjd/ljad319.

Author

Antonia Lloyd-Lavery¹

Affiliation

¹ Department of Dermatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

PMID: 37658936
DOI: 10.1093/bjd/ljad319

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest the author declares no conflicts of interest.

Comment on

Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A, Katsunuma T, Matsumura T, Komazaki H; Nemolizumab-JP04 Study Group. Igarashi A, et al. Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268. Br J Dermatol. 2023. PMID: 37522351 Clinical Trial.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems